Cargando…

The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study

BACKGROUND: In 2013 American College of Cardiology and the American Heart Association released a guideline on the management of atherosclerotic cardiovascular disease (ASCVD) including a composite of death from CVD, non-fatal myocardial infarction, or non-fatal stroke (hard CVD). This guideline reco...

Descripción completa

Detalles Bibliográficos
Autores principales: Hadaegh, Farzad, Asgari, Samaneh, Moosaie, Fatemeh, Orangi, Meysam, Sarvghadi, Farzaneh, Khalili, Davood, Azizi, Fereidoun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789723/
https://www.ncbi.nlm.nih.gov/pubmed/33407576
http://dx.doi.org/10.1186/s12967-020-02686-1
_version_ 1783633302966501376
author Hadaegh, Farzad
Asgari, Samaneh
Moosaie, Fatemeh
Orangi, Meysam
Sarvghadi, Farzaneh
Khalili, Davood
Azizi, Fereidoun
author_facet Hadaegh, Farzad
Asgari, Samaneh
Moosaie, Fatemeh
Orangi, Meysam
Sarvghadi, Farzaneh
Khalili, Davood
Azizi, Fereidoun
author_sort Hadaegh, Farzad
collection PubMed
description BACKGROUND: In 2013 American College of Cardiology and the American Heart Association released a guideline on the management of atherosclerotic cardiovascular disease (ASCVD) including a composite of death from CVD, non-fatal myocardial infarction, or non-fatal stroke (hard CVD). This guideline recommended a risk score that was calculated using pooled cohort equations (ASCVD-PCE). The guideline was updated in 2018/2019 and further risk discussion was suggested for deciding whether to continue or initiate statin therapy among non-diabetic individuals with ASCVD-PCE score ranged 5–20%. They recommended a risk discussion with considering risk enhancing factors (ASCVD-REFs) including family history of premature CVD, chronic kidney disease, triglycerides ≥ 175 mg/dl, low-density lipoprotein cholesterol (LDL-C) ≥ 160 mg/dl, metabolic syndrome (Mets), and for women premature menopause, and hypertensive disorders of pregnancy (HDP). In the current study, we aimed to examine the predictability of recommended ASCVD-REFs on incident hard CVD in non-diabetic individuals with LDL-C 70-189 mg/dl, with ASCVD-PCE risk 5–20% during 10 and 15-year follow-up. METHODS: Among a total of 3546 non-diabetic individuals aged 40-75 years, after excluding those with ASCVD-PCE score < 5% and ≥ 20% (n = 2342), 1204 individuals (women = 332) were included. The univariable and multivariable (further adjusted for ASCVD-PCE) Cox regression analysis were used to evaluate the association of each potential ASCVD-REFs with hard CVD. Additionnaly, the role of different components of Mets and a history of gestational diabetes (GDM)/macrosomia was also examined. The predictive ability of each significant ASCVD-REFs, then was evaluated by the discrimination accuracy and risk reclassification index. RESULTS: During the 10-year follow-up, 73 hard CVD events occurred. Although in univariable analysis, high blood pressure (BP) component of Mets, GDM/macrosomia, and HDP remained as significant ASCVD-REFs, in the multivariable analysis, only the history of HDP (5.35 (1.22–23.38)) and GDM/macrosomia (3.18 (1.05–9.65)) showed independent risks. During the 15-year follow-up, Mets (1.47 (1.05–2.06)) and its components of high waist circumference (1.40 (1.0–1.95)) and high BP (1.52 (1.07–2.15)) significantly increased the risk. These ASCVD-REFs did not improve discrimination or predictive ability. CONCLUSIONS: In a decade follow-up, only conditions specific for women and in longer follow-up, the presence of Mets perse, and its components of high WC and high BP were shown as significant ASCVD-REFs.
format Online
Article
Text
id pubmed-7789723
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77897232021-01-07 The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study Hadaegh, Farzad Asgari, Samaneh Moosaie, Fatemeh Orangi, Meysam Sarvghadi, Farzaneh Khalili, Davood Azizi, Fereidoun J Transl Med Research BACKGROUND: In 2013 American College of Cardiology and the American Heart Association released a guideline on the management of atherosclerotic cardiovascular disease (ASCVD) including a composite of death from CVD, non-fatal myocardial infarction, or non-fatal stroke (hard CVD). This guideline recommended a risk score that was calculated using pooled cohort equations (ASCVD-PCE). The guideline was updated in 2018/2019 and further risk discussion was suggested for deciding whether to continue or initiate statin therapy among non-diabetic individuals with ASCVD-PCE score ranged 5–20%. They recommended a risk discussion with considering risk enhancing factors (ASCVD-REFs) including family history of premature CVD, chronic kidney disease, triglycerides ≥ 175 mg/dl, low-density lipoprotein cholesterol (LDL-C) ≥ 160 mg/dl, metabolic syndrome (Mets), and for women premature menopause, and hypertensive disorders of pregnancy (HDP). In the current study, we aimed to examine the predictability of recommended ASCVD-REFs on incident hard CVD in non-diabetic individuals with LDL-C 70-189 mg/dl, with ASCVD-PCE risk 5–20% during 10 and 15-year follow-up. METHODS: Among a total of 3546 non-diabetic individuals aged 40-75 years, after excluding those with ASCVD-PCE score < 5% and ≥ 20% (n = 2342), 1204 individuals (women = 332) were included. The univariable and multivariable (further adjusted for ASCVD-PCE) Cox regression analysis were used to evaluate the association of each potential ASCVD-REFs with hard CVD. Additionnaly, the role of different components of Mets and a history of gestational diabetes (GDM)/macrosomia was also examined. The predictive ability of each significant ASCVD-REFs, then was evaluated by the discrimination accuracy and risk reclassification index. RESULTS: During the 10-year follow-up, 73 hard CVD events occurred. Although in univariable analysis, high blood pressure (BP) component of Mets, GDM/macrosomia, and HDP remained as significant ASCVD-REFs, in the multivariable analysis, only the history of HDP (5.35 (1.22–23.38)) and GDM/macrosomia (3.18 (1.05–9.65)) showed independent risks. During the 15-year follow-up, Mets (1.47 (1.05–2.06)) and its components of high waist circumference (1.40 (1.0–1.95)) and high BP (1.52 (1.07–2.15)) significantly increased the risk. These ASCVD-REFs did not improve discrimination or predictive ability. CONCLUSIONS: In a decade follow-up, only conditions specific for women and in longer follow-up, the presence of Mets perse, and its components of high WC and high BP were shown as significant ASCVD-REFs. BioMed Central 2021-01-06 /pmc/articles/PMC7789723/ /pubmed/33407576 http://dx.doi.org/10.1186/s12967-020-02686-1 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hadaegh, Farzad
Asgari, Samaneh
Moosaie, Fatemeh
Orangi, Meysam
Sarvghadi, Farzaneh
Khalili, Davood
Azizi, Fereidoun
The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study
title The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study
title_full The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study
title_fullStr The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study
title_full_unstemmed The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study
title_short The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study
title_sort risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: tehran lipid and glucose study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789723/
https://www.ncbi.nlm.nih.gov/pubmed/33407576
http://dx.doi.org/10.1186/s12967-020-02686-1
work_keys_str_mv AT hadaeghfarzad theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy
AT asgarisamaneh theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy
AT moosaiefatemeh theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy
AT orangimeysam theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy
AT sarvghadifarzaneh theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy
AT khalilidavood theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy
AT azizifereidoun theriskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy
AT hadaeghfarzad riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy
AT asgarisamaneh riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy
AT moosaiefatemeh riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy
AT orangimeysam riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy
AT sarvghadifarzaneh riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy
AT khalilidavood riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy
AT azizifereidoun riskandaddedvaluesoftheatheroscleroticcardiovascularriskenhancersonpredictionofcardiovasculareventstehranlipidandglucosestudy